## Abstract The purpose of this study was to investigate the causes for the differences observed in the pharmacokinetics of YJAโ20379โ8 in 16โweekโold spontaneously hypertensive rats (SHRs). To see if the hereditary characteristics of SHRs was the cause, 20 mg/kg of the drug was intravenously infus
Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt induced hypertensive rats
โ Scribed by Kye S. Han; Sun H. Lee; Myung G. Lee; Nak D. Kim
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 810 KB
- Volume
- 14
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
The pharmacokinetics and pharmacodynamics of bumetanide were investigated after intravenous (i.v.) administration, 10 mg kg^โ1^, and oral administration, 20 mg kg^โ1^, to spontaneously hypertensive rats (SHRs) and deoxycorticosterone acetateโsalt induced hypertensive rats (DOCAโsalt rats). After i.v. administration, the pharmacokinetic and pharmacodynamic parameters of bumetanide did not vary significantly between SHRs and the control Wistar rats. Similar results were also shown between DOCAโsalt rats and the control SpragueโDawley (SD) rats. After oral administration, the AUC~0โ12 h~ decreased significantly (186 versus 335 ฮผg min ml^โ1^) in SHRs and this resulted in decreased F(15.4 versus 23.6 and 2.78 versus 5.76% using two equations) in SHRs when compared with the control Wistar rats, although none of the other pharmacokinetic parameters varied significantly between SHRs and Wistar rats. This effect seemed to be due to the decreased enterohepatic recirculation of bumetanide in SHRs: the amounts of both bumetanide and its glucuronide product, which are capable of enterohepatic recirculation, excreted in 8 h bile juice decreased significantly in SHRs (11.3 versus 37.4 ฮผg as expressed in terms of bumetanide) when compared with Wistar rats. The pharmacodynamic parameters did not vary significantly between SHRs and Wistar rats after oral administration of bumetanide. The pharmacokinetic and pharmacodynamic parameters of bumetanide did not vary significantly between DOCAโsalt rats and SD rats after oral administration of the drug. The liver weights compared to body weight increased significantly in SHRs when compared with Wistar rats and the corresponding values for the kidney increased significantly in DOCAโsalt rats when compared with SD rats.
๐ SIMILAR VOLUMES
Because some physiological changes occurring in diabetes mellitus patients could alter the pharmacokinetics and pharmacodynamics of the drugs to treat the disease, the pharmacokinetics and pharmacodynamics of furosemide were investigated after intravenous (i.v.) and oral administration of the drug (
The pharmacokinetic and pharmacodynamic differences of azosemide were investigated after intravenous (IV) and oral administration of azosemide, 10 mg kg -1 , to the control and uranyl nitrate-induced acute renal failure (U-ARF) rats. After IV administration, the plasma concentrations of azosemide we